Table 1:

Low, intermediate, and high-risk features for development of CTRCT. A patient should be grouped with their highest individual risk factor.

Risk Factor Categories for CTRCT
Low Risk	Age 18–50 years Cumulative dose <200 mg/m2 doxorubicin (or equivalent) No pre-existing or new CVD risk factors* Cumulative RT dose <30 Gy without chest involvement
Intermediate Risk	Age 50–65 years Cumulative dose 200–400 mg/m2 doxorubicin (or equivalent) 1–2 pre-existing or new CVD risk factors* Cumulative RT dose >30 Gy without chest involvement Single-agent targeted therapy or immunotherapy
High Risk	Age <18 or >65 years Cumulative dose >400 mg/m2 doxorubicin (or equivalent) Any RT involving the chest Any combination of cardiotoxic cancer therapies, even within same class >2 pre-existing or new CVD risk factors* Underlying CVD (CAD, HF, PAD, etc.) History of CTRCT

^*CVD risk factors include, but are not limited to, hypertension, insulin resistance, diabetes mellitus, smoking, obesity, and dyslipidemia.

Abbreviations: CAD, coronary artery disease; CTRCT, cancer therapy-related cardiotoxicity; CVD, cardiovascular disease; Gy, Gray unit(s); HF, heart failure; PAD, peripheral artery disease; RT, radiation therapy